Allison Inserro

September 23, 2021

Long-awaited reports released Thursday call for eliminating race in estimated glomerular filtration rate equations and point to alternatives in an effort to eliminate disparities in chronic kidney disease.

September 21, 2021

An updated report shows that the long-term cost of treating the health effects of polycystic ovary syndrome (PCOS)—$4.3 billion—is even higher than $3.7 billion it takes to diagnose and treat immediate issues that present for women who are of reproductive age.

September 19, 2021

A systematic review that aimed to find out more about how growth hormone deficiency (GHD) affects children's oral and dental development found that knowledge gaps still remain.

September 18, 2021

Real-world outcomes can differ from those seen in tightly-controlled clinical trials, so researchers wanted to examine the patterns of growth hormone treatment in a large cohort of children in Israel.

September 17, 2021

The advisory committee voted against COVID-19 vaccine booster shots for individuals 16 years and older, but unanimously voted for booster shots for people 65 years and older or who are at high risk of severe COVID-19.

September 12, 2021

Innovative therapies for rare diseases such as spinal muscular atrophy (SMA), when paid for by public budgets in the European Union and elsewhere, are often managed by agreements between payers and drug companies, but details can be hard to discern.

September 11, 2021

Investigators examined medical records spanning 3 decades to look at the effect of poorly differentiated tumor size on outcomes in survival in hepatocellular carcinoma (HCC).

September 10, 2021

Neuropalliative care is an emerging field for those with conditions such as Parkinson disease, multiple system atrophy, progressive supranuclear palsy, corticobasal syndrome, and other diseases, but access to care remains limited, according to a recent survey.

September 09, 2021

The Department of Labor rules will affect employers with 100 or more workers.

September 09, 2021

The administration said it would make the results of its drug price negotiations with manufacturers, as well as its approach to value-based care models, open to a variety of payers.